Novartis buys Fougera for $1.5 billion cash to boost Sandoz dermatology business
This article was originally published in Scrip
Novartis will pay $1.5 billion in cash to acquire the private, specialized US firm Fougera Pharmaceuticals and make its generics division Sandoz the number one generic dermatology medicines company in the world with an estimated $620 million in annual global sales.
You may also be interested in...
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.